中国临床解剖学杂志 ›› 2019, Vol. 37 ›› Issue (2): 169-173.doi: 10.13418/j.issn.1001-165x.2019.02.011

• 实验研究 • 上一篇    下一篇

黄芪多糖通过JAK/STAT3通路抑制口腔鳞癌SCC-25裸鼠移植瘤

邓力, 蔡婷, 王静雷, 夏雨, 周智   

  1. 重庆医科大学附属口腔医院预防口腔科, 口腔疾病与生物医学重庆市重点实验室,
    重庆市高校市级口腔生物医学工程重点实验室,  重庆   401147
  • 收稿日期:2018-11-08 出版日期:2019-03-25 发布日期:2019-04-29
  • 通讯作者: 周智,教授, E-mail: zhizhoucq@sina.com
  • 作者简介:邓力(1992-),硕士研究生,医师,研究方向:口腔流行病学调查以及口腔循证医学,E-mail:diming62625107@sina.com,Tel:13983005637
  • 基金资助:

    重庆市卫生和计划生育委员会医学科研项目资助(2017ZDXM018);重庆高校创新团队建设计划资助项目(CXTDG201602006);重庆市高校市级口腔生物医学工程重点实验室资助项目[渝科教(2014)55号]

Astragalus polysaccharide inhibits oral squamous cell carcinoma cell line SCC-25 xenograft tumor by suppressing JAK/STAT3 signaling pathway

DENG Li, CAI Ting, WANG Jing-xue, XIA Yu, ZHOU Zhi   

  1. Department of preventive stomatology,Stomatological Hospital of Chongqing Medical University;Chongqing Key Laboratory of Oral Diseases and Biomedical  Sciences;Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing 401147, China
  • Received:2018-11-08 Online:2019-03-25 Published:2019-04-29

摘要:

 目的 阐明黄芪多糖(AP)对口腔鳞癌(oral squamous cell carcinoma)细胞系SCC-25移植瘤模型小鼠的影响和机制。  方法 皮下注射口腔鳞癌细胞系SCC-25建立异种移植瘤模型,将移植瘤BALB/c裸鼠模型随机分为4组:对照组(cTRL)、AP低剂量组(AP 10 mg)、AP中剂量组(AP 25 mg)和AP高剂量组(AP 50 mg)。AP治疗后,检测移植瘤体积和小鼠存活率;免疫组化检测Ki67和血管内皮生长因子(vascular endothelial growth factor,VEGF)表达水平;TUNEL实验检测移植瘤细胞凋亡情况;Western blot 检测JAK2/STAT3通路蛋白表达情况和磷酸化情况。  结果 与对照组相比较,AP低、中、高剂量组肿瘤体积明显减小(P<0.01),小鼠存活率明显增加(P<0.01),Ki67和VEGF表达水平明显下降(P<0.01),JAK2/STAT3/c-myc磷酸化水平明显被抑制(P<0.01)。  结论 AP以剂量依赖抑制SCC-25移植瘤体积,提高移植瘤小鼠存活率,下调Ki67和VEGF表达水平和JAK2/STAT3磷酸化水平。AP可能通过抑制JAK2/STAT3/c-myc信号通路抑制口腔鳞癌细胞SCC-25移植瘤生长。

关键词: 黄芪多糖,  口腔鳞癌,  移植瘤模型小鼠,  JAK2/STAT3

Abstract:

Objective To elucidate the effect and mechanism of astragalus polysaccharide (AP) on SCC-25 xenograft tumor model mice in oral squamous cell carcinoma (OSCC) cell line. Methods The xenograft tumor model was established by subcutaneous injection of oral squamous cell carcinoma cell line SCC-25, and the xenograft tumor BALB/c nude mice models were randomly divided into 4 groups: a control group (cTRL), an AP low-dose group (AP 10 mg), an AP medium-dose group (AP 25 mg) and an AP high-dose group (AP 50 mg) for subsequent experiments. After treatment with AP, the tumor volume and survival rate of mice were measured. The expression of Ki67 and vascular endothelial growth factor (VEGF) were detected by immunohistochemistry. Apoptosis of xenograft tumor cells was detected by TUNEL assay. Protein expression of JAK2/STAT3 pathway members was detected by Western blot. Results Compared with the control group, the tumor volume of the low, medium and high-dose groups were decreased significantly (P<0.01), and the survival rate of the mice was increased significantly in AP treated groups (P<0.01). In addition, the expression levels of Ki67 and VEGF were decreased significantly (P<0.01), and the phosphorylation levels of JAK2/STAT3/c-myc were significantly inhibited (P<0.01). Conclusion AP inhibits the growth of SCC-25 xenograft tumors in a dose-dependent manner; particularly, AP increases the survival rate of xenograft tumor mice, and down-regulates the expression levels of Ki67 and VEGF and the phosphorylation level of JAK2/STAT3/c-myc. AP may inhibit oral squamous cell line SCC-25 xenograft tumor by inhibiting JAK2/STAT3/c-myc signaling pathway.